SEC 13F Intelligence

Managers / Q1 2026

BML Capital Management, LLC

CIK 0001616824 · 65 E CEDAR - SUITE 2, ZIONSVILLE, IN, 46077 · 317-344-2447

Reported Value
$156M
Q1 2026
Positions
16
Filings on Record
16
2019–present window
Filed
May 6, 2026
original filing

Summary

Bml Capital Management, LLC reported $156M in U.S.-listed holdings across 16 positions for Q1 2026.

The portfolio is heavily concentrated: ACRS alone accounts for 34.3% of reported value.

Compared with Q4 2025, the fund opened 3 new positions and exited 3.

Portfolio Metrics

Turnover
+3.4%
vs prior filed quarter
Top-10 Concentration
+94.0%
share of reported value
Largest Position
+34.3%
Aclaris Therapeutics
New / Exited
3 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $105MQ4 ’22Q1 ’23: $116MQ2 ’23: $111MQ2 ’23Q3 ’23: $109MQ4 ’23: $132MQ4 ’23Q1 ’24: $152MQ2 ’24: $140MQ2 ’24Q3 ’24: $170MQ4 ’24: $161MQ4 ’24Q1 ’25: $124MQ2 ’25: $132MQ2 ’25Q3 ’25: $109MQ4 ’25: $116MQ4 ’25Q1 ’26: $156Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 99.3%Other: 0.7%
  • Common Stock · 99.3% · $155M
  • Other · 0.7% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TILLYS INCNEW+2.15M2.15M+$9M$9M
KHCKRAFT HEINZ CONEW+125.0K125.0K+$3M$3M
JANXJANUX THERAPEUTICS INCNEW+155.0K155.0K+$2M$2M
OMOUTSET MED INCADDED+1.36M1.90M+$5M$7M
CVNACARVANA COSOLD OUT−1500−$2M$0
TSLATESLA INCSOLD OUT−1.0K0−$205,000$0
LSTALISATA THERAPEUTICS INCSOLD OUT−73.3K0−$136,427$0
IMAIMAGENEBIO INCADDED+23.7K200.7K−$217,829$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

15 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ACRSACLARIS THERAPEUTICS INChistory →COM34.31%$53M14.25M
2AVIRATEA PHARMACEUTICALS INChistory →COM24.38%$38M7.06M
3ORMPORAMED PHARMACEUTICALS INChistory →COM NEW6.91%$11M3.17M
4TILLYS INCCL A5.59%$9M2.15M
5OMOUTSET MED INChistory →COM NEW4.69%$7M1.90M
6PMVPPMV PHARMACEUTICALS INChistory →COM4.24%$7M5.32M
7KMXCARMAX INChistory →COM4.14%$6M155.0K
82KZ0KEZAR LIFE SCIENCES INChistory →COM NEW3.43%$5M720.8K
9TILINSTIL BIO INChistory →COM NEW3.42%$5M645.6K
10DYHTARGET CORPhistory →COM2.92%$5M37.5K
11KHCKRAFT HEINZ COhistory →COM1.80%$3M125.0K
12JANXJANUX THERAPEUTICS INChistory →COM1.38%$2M155.0K
13PLRXPLIANT THERAPEUTICS INChistory →COM1.25%$2M1.55M
14CONNECT BIOPHARMA HLDGS LTDSHS0.69%$1M408.9K
15IMAIMAGENEBIO INCCOM0.64%$1M200.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$156M16May 6, 202613F-HRchanges · EDGAR ↗
Q4 2025$116M16Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M20Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$132M24Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$124M27May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$161M25Feb 7, 202513F-HRchanges · EDGAR ↗
Q3 2024$170M29Nov 5, 202413F-HRchanges · EDGAR ↗
Q2 2024$140M28Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$152M32Apr 24, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$132M35Feb 2, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$109M26Oct 23, 202313F-HRchanges · EDGAR ↗
Q2 2023$111M31Jul 24, 202313F-HRchanges · EDGAR ↗
Q1 2023$116M31Apr 14, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M25Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.